A citation-based method for searching scientific literature

Andreas Schneeweiss, Andreas D Hartkopf, Volkmar Müller, Achim Wöckel, Michael P Lux, Wolfgang Janni, Johannes Ettl, Erik Belleville, Jens Huober, Marc Thill, Peter A Fasching, Hans-Christian Kolberg, Patrik Pöschke, Manfred Welslau, Friedrich Overkamp, Hans Tesch, Tanja N Fehm, Diana Lüftner, Florian Schütz. Geburtshilfe Frauenheilkd 2020
Times Cited: 10







List of co-cited articles
15 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics.
Diana Lüftner, Andreas Schneeweiss, Andreas D Hartkopf, Volkmar Müller, Achim Wöckel, Wolfgang Janni, Johannes Ettl, Erik Belleville, Florian Schütz, Marc Thill,[...]. Geburtshilfe Frauenheilkd 2020
5
100

Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer.
Hans Tesch, Volkmar Müller, Achim Wöckel, Johannes Ettl, Erik Belleville, Florian Schütz, Andreas Hartkopf, Marc Thill, Jens Huober, Peter A Fasching,[...]. Geburtshilfe Frauenheilkd 2020
4
75

Update Breast Cancer 2020 Part 3 - Early Breast Cancer.
Jens Huober, Andreas Schneeweiss, Andreas D Hartkopf, Volkmar Müller, Michael P Lux, Wolfgang Janni, Johannes Ettl, Erik Belleville, Marc Thill, Peter A Fasching,[...]. Geburtshilfe Frauenheilkd 2020
6
50

Pembrolizumab for Early Triple-Negative Breast Cancer.
Peter Schmid, Javier Cortes, Lajos Pusztai, Heather McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck,[...]. N Engl J Med 2020
605
20

Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer.
Florian Schütz, Peter A Fasching, Manfred Welslau, Andreas D Hartkopf, Achim Wöckel, Michael P Lux, Wolfgang Janni, Johannes Ettl, Diana Lüftner, Erik Belleville,[...]. Geburtshilfe Frauenheilkd 2019
11
20

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Aditya Bardia, Ingrid A Mayer, Linda T Vahdat, Sara M Tolaney, Steven J Isakoff, Jennifer R Diamond, Joyce O'Shaughnessy, Rebecca L Moroose, Alessandro D Santin, Vandana G Abramson,[...]. N Engl J Med 2019
306
20

Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel.
Hans-Christian Kolberg, Andreas Schneeweiss, Tanja N Fehm, Achim Wöckel, Jens Huober, Constanza Pontones, Adriana Titzmann, Erik Belleville, Michael P Lux, Wolfgang Janni,[...]. Geburtshilfe Frauenheilkd 2019
18
20

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
Stephen R D Johnston, Nadia Harbeck, Roberto Hegg, Masakazu Toi, Miguel Martin, Zhi Min Shao, Qing Yuan Zhang, Jorge Luis Martinez Rodriguez, Mario Campone, Erika Hamilton,[...]. J Clin Oncol 2020
163
20

Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy.
Elizabeth A Mittendorf, Jacqueline S Jeruss, Susan L Tucker, Aparna Kolli, Lisa A Newman, Ana M Gonzalez-Angulo, Thomas A Buchholz, Aysegul A Sahin, Janice N Cormier, Aman U Buzdar,[...]. J Clin Oncol 2011
87
20

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Rashmi K Murthy, Sherene Loi, Alicia Okines, Elisavet Paplomata, Erika Hamilton, Sara A Hurvitz, Nancy U Lin, Virginia Borges, Vandana Abramson, Carey Anders,[...]. N Engl J Med 2020
400
20

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Peter Schmid, Sylvia Adams, Hope S Rugo, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Roberto Hegg, Seock-Ah Im, Gail Shaw Wright,[...]. N Engl J Med 2018
20

Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer.
Andreas D Hartkopf, Volkmar Müller, Achim Wöckel, Michael P Lux, Wolfgang Janni, Naiba Nabieva, Florin-Andrei Taran, Johannes Ettl, Diana Lüftner, Erik Belleville,[...]. Geburtshilfe Frauenheilkd 2019
10
20

Association analysis identifies 65 new breast cancer risk loci.
Kyriaki Michailidou, Sara Lindström, Joe Dennis, Jonathan Beesley, Shirley Hui, Siddhartha Kar, Audrey Lemaçon, Penny Soucy, Dylan Glubb, Asha Rostamianfar,[...]. Nature 2017
583
20

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019.
Nina Ditsch, Michael Untch, Marc Thill, Volkmar Müller, Wolfgang Janni, Ute-Susann Albert, Ingo Bauerfeind, Jens Blohmer, Wilfried Budach, Peter Dall,[...]. Breast Care (Basel) 2019
44
20

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020.
Nina Ditsch, Michael Untch, Cornelia Kolberg-Liedtke, Christian Jackisch, David Krug, Michael Friedrich, Wolfgang Janni, Volkmar Müller, Ute-Susann Albert, Malgorzata Banys-Paluchowski,[...]. Breast Care (Basel) 2020
24
20


Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era.
Gabriel S Macedo, Barbara Alemar, Patricia Ashton-Prolla. Genet Mol Biol 2019
12
10

Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.
R B Egerdie, F Saad, M R Smith, T L J Tammela, J Heracek, P Sieber, C Ke, B Leder, R Dansey, C Goessl. Prostate Cancer Prostatic Dis 2012
12
10

Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
Daniel G Branstetter, Scott D Nelson, J Carlos Manivel, Jean-Yves Blay, Sant Chawla, David M Thomas, Susie Jun, Ira Jacobs. Clin Cancer Res 2012
275
10

Denosumab in early-stage breast cancer - Authors' reply.
Michael Gnant, Georg Pfeiler, Sophie Frantal. Lancet Oncol 2019
2
50

American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.
Salvatore L Ruggiero, Thomas B Dodson, John Fantasia, Reginald Goodday, Tara Aghaloo, Bhoomi Mehrotra, Felice O'Ryan. J Oral Maxillofac Surg 2014
10

A systematic review of the international prevalence of BRCA mutation in breast cancer.
Nigel Armstrong, Steve Ryder, Carol Forbes, Janine Ross, Ruben Gw Quek. Clin Epidemiol 2019
71
10

Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.
Matthew R Smith, Fred Saad, Stephane Oudard, Neal Shore, Karim Fizazi, Paul Sieber, Bertrand Tombal, Ronaldo Damiao, Gavin Marx, Kurt Miller,[...]. J Clin Oncol 2013
142
10

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Michael Gnant, Georg Pfeiler, Peter C Dubsky, Michael Hubalek, Richard Greil, Raimund Jakesz, Viktor Wette, Marija Balic, Ferdinand Haslbauer, Elisabeth Melbinger,[...]. Lancet 2015
298
10

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Noopur Raje, Evangelos Terpos, Wolfgang Willenbacher, Kazuyuki Shimizu, Ramón García-Sanz, Brian Durie, Wojciech Legieć, Marta Krejčí, Kamel Laribi, Li Zhu,[...]. Lancet Oncol 2018
197
10

The sex hormone system in carriers of BRCA1/2 mutations: a case-control study.
Martin Widschwendter, Adam N Rosenthal, Sue Philpott, Ivana Rizzuto, Lindsay Fraser, Jane Hayward, Maria P Intermaggio, Christopher K Edlund, Susan J Ramus, Simon A Gayther,[...]. Lancet Oncol 2013
80
10

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017
10

Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis.
Prakirthi Yerram, Shraddha Kansagra, Osama Abdelghany. J Oncol Pharm Pract 2017
14
10

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
P Hadji, R E Coleman, C Wilson, T J Powles, P Clézardin, M Aapro, L Costa, J-J Body, C Markopoulos, D Santini,[...]. Ann Oncol 2016
117
10

OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer.
Nicole Sänger, Eugen Ruckhäberle, Giampaolo Bianchini, Tomas Heinrich, Karin Milde-Langosch, Volkmar Müller, Achim Rody, Erich Franz Solomayer, Tanja Fehm, Uwe Holtrich,[...]. Mol Oncol 2014
17
10

RANKL/RANK control Brca1 mutation- .
Verena Sigl, Kwadwo Owusu-Boaitey, Purna A Joshi, Anoop Kavirayani, Gerald Wirnsberger, Maria Novatchkova, Ivona Kozieradzki, Daniel Schramek, Nnamdi Edokobi, Jerome Hersl,[...]. Cell Res 2016
93
10

RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Marco Infante, Alessandra Fabi, Francesco Cognetti, Stefania Gorini, Massimiliano Caprio, Andrea Fabbri. J Exp Clin Cancer Res 2019
53
10

Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer.
Stefan Kiechl, Daniel Schramek, Martin Widschwendter, Evangelia-Ourania Fourkala, Alexey Zaikin, Allison Jones, Bernadette Jaeger, Brigitte Rack, Wolfgang Janni, Christoph Scholz,[...]. Oncotarget 2017
30
10

The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases.
Arlindo Ferreira, Irina Alho, Inês Vendrell, Marta Melo, Raquel Brás, Ana Lúcia Costa, Ana Rita Sousa, André Mansinho, Catarina Abreu, Catarina Pulido,[...]. Oncotarget 2016
6
16

RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
Emma Nolan, François Vaillant, Daniel Branstetter, Bhupinder Pal, Göknur Giner, Lachlan Whitehead, Sheau W Lok, Gregory B Mann, Kathy Rohrbach, Li-Ya Huang,[...]. Nat Med 2016
167
10

Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy.
Eleni Timotheadou, Konstantine T Kalogeras, Georgia-Angeliki Koliou, Ralph M Wirtz, Flora Zagouri, Angelos Koutras, Elke Veltrup, Christos Christodoulou, George Pentheroudakis, Aris Tsiftsoglou,[...]. Transl Oncol 2017
12
10

AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2018.
Marc Thill, Cornelia Liedtke, Volkmar Müller, Wolfgang Janni, Marcus Schmidt. Breast Care (Basel) 2018
14
10

The dilemma of denosumab: Salvage of a femoral head giant cell tumour.
Czar Louie Gaston, Florian Puls, Robert John Grimer. Int J Surg Case Rep 2014
7
14

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
Georgiana K Ellis, Henry G Bone, Rowan Chlebowski, Devchand Paul, Silvana Spadafora, Judy Smith, Michelle Fan, Susie Jun. J Clin Oncol 2008
315
10

BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.
Elisabet Cuyàs, Bruna Corominas-Faja, María Muñoz-San Martín, Begoña Martin-Castillo, Ruth Lupu, Joan Brunet, Joaquim Bosch-Barrera, Javier A Menendez. Oncotarget 2017
11
10

Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies.
C Thongprayoon, P Acharya, C Acharya, J Chenbhanich, T Bathini, B Boonpheng, K Sharma, K Wijarnpreecha, P Ungprasert, M L Gonzalez Suarez,[...]. Osteoporos Int 2018
25
10


Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
10

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer.
Daniel Schramek, Andreas Leibbrandt, Verena Sigl, Lukas Kenner, John A Pospisilik, Heather J Lee, Reiko Hanada, Purna A Joshi, Antonios Aliprantis, Laurie Glimcher,[...]. Nature 2010
418
10

[Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
B Svejda, Ch Muschitz, R Gruber, Ch Brandtner, Ch Svejda, R W Gasser, G Santler, H P Dimai. Wien Med Wochenschr 2016
23
10

Serum osteoprotegerin and future risk of cancer and cancer-related mortality in the general population: the Tromsø study.
Anders Vik, Ellen E Brodin, Ellisiv B Mathiesen, Jan Brox, Lone Jørgensen, Inger Njølstad, Sigrid K Brækkan, John-Bjarne Hansen. Eur J Epidemiol 2015
19
10

Progesterone induces adult mammary stem cell expansion.
Purna A Joshi, Hartland W Jackson, Alexander G Beristain, Marco A Di Grappa, Patricia A Mote, Christine L Clarke, John Stingl, Paul D Waterhouse, Rama Khokha. Nature 2010
500
10


Adjuvant denosumab in early breast cancer.
Manuel Scimeca, Rita Bonfiglio, Nicoletta Urbano, Orazio Schillaci, Elena Bonanno. Lancet Oncol 2020
3
33

Denosumab: benefits of RANK ligand inhibition in cancer patients.
Allan Lipton, Ira Jacobs. Curr Opin Support Palliat Care 2011
18
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.